Quote:
Originally Posted by Erin524
I'm trying to find actual medical journal papers that tell about the few trials with LDN. My regular neuro said that he doesnt want printouts from the internet. He wants something from specific Neurology journals before he'll even consider LDN. (and I'd probably have to be a paying subscriber to any of the journals he reads...and they probably dont have any of the research in those journals yet)
|
Pubmed is an extremely reliable source. Tell him to look "A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis" at Pubmed.
I think it was published in a Journal too . . . try googling that title and see if it pops up in any Neurology Journals.
Mult Scler. 2008 Sep;14(8):1076-83.
A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis
Gironi M, Martinelli-Boneschi F, Sacerdote P, Solaro C, Zaffaroni M, Cavarretta R, Moiola L, Bucello S, Radaelli M, Pilato V, Rodegher M, Cursi M, Franchi S, Martinelli V, Nemni R, Comi G, Martino G.
Institute of Experimental Neurology (INSPE) and Department of Neurology, San Raffaele Scientific Institute, Via Olgettina 58, Milan, Italy; Fondazione Don Carlo Gnocchi, IRCCS, Milan, Italy.
A sixth month phase II multicenter-pilot trial with a low dose of the opiate antagonist Naltrexone (LDN) has been carried out in 40 patients with primary progressive multiple sclerosis (PPMS). The primary end points were safety and tolerability. Secondary outcomes were efficacy on spasticity, pain, fatigue, depression, and quality of life. Clinical and biochemical evaluations were serially performed. Protein concentration of beta-endorphins (BE) and mRNA levels and allelic variants of the mu-opiod receptor gene (OPRM1) were analyzed.
Five dropouts and two major adverse events occurred. The remaining adverse events did not interfere with daily living. Neurological disability progressed in only one patient. A significant reduction of spasticity was measured at the end of the trial. BE concentration increased during the trial, but no association was found between OPRM1 variants and improvement of spasticity.
Our data clearly indicate that LDN is safe and well tolerated in patients with PPMS.
PMID: 18728058
Cherie
__________________
I am not a Neurologist, Physician, Nurse, or Hairdresser ... but I have learned that it is not such a great idea to give oneself a haircut after three margaritas
.